| No headlines available for RYCFX. |
|
|
| Morningstar Overall Rating: |
 |
| Total Assets: |
3.77M |
| Category: |
Health |
| Total Expense Ratio: |
2.39% |
|
| PERFORMANCE & RISK | 31-Jan-10
| YTD Return: |
3.73% |
| 5y Avg Return: |
4.98% |
| Rank in Category (ytd): |
6 |
| % Rank in Category (ytd): |
3.61% |
| Beta (3y): |
0.73 |
| Morningstar Risk Rating: |
Above average |
|
| The investment seeks capital appreciation. The fund invests substantially at least 80% of its net assets in equity securities of Biotechnology Companies that are traded in the United States and derivatives. Biotechnology Companies are engaged in the research, development, and manufacture of various biotechnologi-cal products, services, and processes; manufacture and/or distribute biotechnological and biomedical products, including devices and instruments; provide or benefit significantly from scientific and technological advances in biotechnology; or provide processes or services instead of, or in addition to, products. It is nondiversified. |
|
| Fund Profile |
|
Help
0.25 (1.09%) 
Summary
Add RYCFX to Portfolio 
Download Data
